Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 14 for:    adjuvant imatinib | GIST

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02413736
Recruitment Status : Recruiting
First Posted : April 10, 2015
Last Update Posted : January 4, 2022
Sponsor:
Collaborator:
Scandinavian Sarcoma Group
Information provided by (Responsible Party):
Heikki Joensuu, Helsinki University Central Hospital

Tracking Information
First Submitted Date  ICMJE April 7, 2015
First Posted Date  ICMJE April 10, 2015
Last Update Posted Date January 4, 2022
Study Start Date  ICMJE May 2015
Estimated Primary Completion Date May 2028   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 9, 2017)
Recurrence-free survival [ Time Frame: 5 years ]
Time from the date of randomization to GIST recurrence or death.
Original Primary Outcome Measures  ICMJE
 (submitted: April 7, 2015)
Recurrence-free survival [ Time Frame: 5 years ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 25, 2018)
  • Overall survival [ Time Frame: 5 years ]
    Time from the date of randomization to death.
  • GIST-specific survival [ Time Frame: 5 years ]
    Time from the date of randomization to the date of death considered to be caused by GIST.
  • Adverse effects [ Time Frame: 5 years ]
    Adverse effects considered to be related to the treatment.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 7, 2015)
  • Overall survival [ Time Frame: 5 years ]
  • GIST-specific survival [ Time Frame: 5 years ]
  • Adverse effects [ Time Frame: 5 years ]
  • Quality of life [ Time Frame: 5 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Official Title  ICMJE Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study
Brief Summary In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) and have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) for 2 more years (Arm A) or to stop imatinib (Arm B). The study participants are required to have histologically verified GIST with a high risk of GIST recurrence despite removal of all macroscopic GIST tissue at surgery and 3 years of adjuvant imatinib. The high risk of GIST recurrence is defined as one of the following: gastric GIST with mitotic count >10/50 high power fields (HPFs) of the microscope, non-gastric GIST with mitotic count >5/50 HPFs, or tumor rupture. Study participants allocated to Arm A will receive imatinib 400 mg/day for 24 months after the date of randomization. All study participants will be followed up using blood tests and computerized tomography (or MRI) of the abdomen. The computerized tomography examinations will be performed at 6 month intervals. A total of 300 patients will be entered to the study. The study hypothesis is that adjuvant imatinib given for a total of 5 years may prevent some of the GISTs to recur as compared to patients who receive adjuvant imatinib for 3 years, and there may be a difference in the rate of GIST recurrence between the two groups.
Detailed Description The study will accrue patients in several countries in the Europe.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Sarcoma
Intervention  ICMJE Drug: Imatinib
Imatinib 400 mg/day
Other Name: Gleevec
Study Arms  ICMJE
  • Experimental: Imatinib
    Imatinib 400 mg/day for 24 months.
    Intervention: Drug: Imatinib
  • No Intervention: No imatinib
    No further imatinib.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 7, 2015)
300
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 2028
Estimated Primary Completion Date May 2028   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥ 18 years.
  • Morphological and immunohistological documentation of GIST (immunostaining for KIT and/or DOG-1 positive, or mutation of KIT or PDGFRA present in tumor tissue).
  • Macroscopically complete surgical resection of GIST (either R0 or R1 resection).
  • Mutation analysis of KIT and PDGFR genes has been carried out.
  • A high risk of GIST recurrence; either gastric GIST with mitotic count >10/50 HPFs, or non-gastric GIST with mitotic count >5/50 HPFs, or tumor rupture.
  • Eastern Cooperative Oncology Group performance status ≤ 2.
  • Adequate organ function.
  • Female patients of childbearing potential must have a negative pregnancy test within 14 days before initiation of study drug dosing. Postmenopausal women must have amenorrhea for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  • Patient willing to be followed up at the study site regardless of the result of randomization.
  • Patient has provided a written, voluntary informed consent prior to study-specific screening procedures.

Exclusion Criteria:

  • Presence of distant metastases or local recurrence of GIST.
  • Not willing to donate tumor tissue and/or blood samples for the study molecular studies.
  • Presence of a substitution mutation at PDGFRA codon D842 (usually D842V).
  • Administration of adjuvant imatinib longer than for 3 years is planned regardless of the result of randomization, or "life long" imatinib administration is planned.
  • Prior adjuvant (+ neoadjuvant) therapy with imatinib mesylate for at least 35 months has not been completed, or the total duration of prior adjuvant (+ neoadjuvant) imatinib administration exceeds the total duration of 37 months.
  • Neoadjuvant imatinib for a duration that exceeds 9 months.
  • Longer than 4-week break during adjuvant imatinib administration.
  • The dose of imatinib at completion of 3 years of adjuvant imatinib was 200 mg per day or less or greater than 800 mg per day.
  • Patient has received any investigational anti-cancer agents during adjuvant imatinib or between completion of adjuvant imatinib and the date of randomization.
  • Patient has been free of another malignancy for less than 5 years except if the other malignancy is not currently clinically significant nor requiring active intervention, or if the other malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Recent existence of any other malignant disease is not allowed.
  • Patient with Grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study entry).
  • Female patients who are pregnant or breast-feeding.
  • Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, severe chronic renal disease, or active uncontrolled infection).
  • Known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient with a significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Heikki Joensuu, MD 094711 ext 358
Contact: Raija Husa 094711 ext 358
Listed Location Countries  ICMJE Finland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02413736
Other Study ID Numbers  ICMJE SSGXXII
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Heikki Joensuu, Helsinki University Central Hospital
Study Sponsor  ICMJE Heikki Joensuu
Collaborators  ICMJE Scandinavian Sarcoma Group
Investigators  ICMJE
Principal Investigator: Heikki Joensuu Helsinki University Central Hospital
PRS Account Helsinki University Central Hospital
Verification Date December 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP